people ventilators; 20% recovery rare,this is good /\'Capricor Therapeutics, Inc. (CAPR)'
Given its novel mechanism of action, it could be a potential game-changer in helping countless COVID-19 patients.”
Capricor is also in late-stage clinical development of CAP-1002 for Duchenne muscular dystrophy (DMD).
In DMD, the lack of dystrophin produces abnormal inflammatory responses, which are responsible for much of the damage to skeletal and cardiac muscle.
The Company has previously announced that top-line results of HOPE-2,
a randomized, placebo-controlled study, will be released by mid-May 2020.
Market Data 
Markets 
AI
